ABvac40
2 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
2
Ongoing
0
Recruiting
0
Completed
2
Sites
23
Countries
4
Endpoints
71
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 71 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 12 of 71 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
2
2
2
2
2
2
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
2 of 2
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT03461276Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD | ABvac40 Alzheimer’s disease, MCI / preclinical Alzheimer’s | Alzheimer's disease | Ph 2 | Completed | 23 | Mar 2023 | 1 | results |
| NCT03113812Repeated Subcutaneous Administration of ABvac40 in Mild to Moderate Alzheimer's Disease Patients | ABvac40 Alzheimer’s disease | Alzheimer's disease | Ph 1 | Completed | 0 | Jul 2015 | 1 |
Showing 1-2 of 2 trials